We knocked down and overexpressed EZH2 in parallel groups of T24 bladder cancer cells (Figure 1), which were subsequently treated with the anticancer drugs, gemcitabine and cis-diamminedichloridoplatinum (II) (cisplatin, DDP), survival rates were assessed in vitro by performing a CD-DST. Here, EZH2 is linked to urinary bladder carcinoma.